|
| Press Releases |
|
 |
|
| Wednesday, August 13, 2025 |
|
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration |
| Essex Bio-Technology Limited ('Essex' or the 'Group', Stock Code: 1061.HK) is pleased to announce that a Biologics License Application ('BLA') for EB12-20145P (HLX04-O), a recombinant anti-VEGF humanized monoclonal antibody injection, has recently been accepted by the Centre for Drug Evaluation ('CDE') of the National Medical Products Administration ('NMPA') in China. The product is jointly developed by the Group and Shanghai Henlius Biotech, Inc. ('Henlius', Stock Code: 2696.HK) for the treatment of wet age-related macular degeneration ('wet-AMD') in China. more info >> |
|
| Friday, July 25, 2025 |
|
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that(Zhuhai Essex Bio-Pharmaceutical Company Limited), an indirect wholly-owned subsidiary, has received approval from (National Medical Products Administration) for the registration and commercialisation of the multi-dose Diquafosol Sodium Eye Drops in the PRC. more info >> |
|
| Monday, March 18, 2024 |
|
|
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1% |
| Essex Bio-Technology Limited ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2023. more info >> |
|
| Wednesday, August 16, 2023 |
|
|
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22% |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the interim results for the six months ended 30 June 2023 ("the period under review").
more info >> |
|
| Wednesday, July 26, 2023 |
|
|
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that a phase 1/2 clinical trial of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
| Friday, April 14, 2023 |
|
|
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore |
| Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Majeton Pte. Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore. more info >> |
|
| Tuesday, April 11, 2023 |
|
|
Essex and Gunze Shenzhen Entered into Exclusive Agency Agreement for PELNAC Absorbable Dressing in Mainland China |
| Essex Bio-Technology Ltd. ("Essex" or the "Group", Stock Code: 1061.HK) is pleased to announce that its wholly-owned subsidiary, Essex Medipharma (Zhuhai) Co., Ltd. ("Essex Medipharma"), has entered into an Agency Agreement ("Agency Agreement") with Gunze Medical Devices (Shenzhen) Ltd. more info >> |
|
| Wednesday, March 8, 2023 |
|
|
Essex Bio-Technology Announces 2022 Annual Financial Results |
Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2022.
more info >> |
|
| Wednesday, February 22, 2023 |
|
|
Essex and Henlius signed amendment agreement for Global Co-Development and Exclusive License Agreement for treatment of age-related macular degeneration |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that two of its wholly-owned subsidiaries, Essex Bio-Investment Limited ("Essex Bio-Investment") and Zhuhai Essex Bio-Pharmaceutical Co. Ltd ("Zhuhai Essex") more info >> |
|
| Friday, February 10, 2023 |
|
|
First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases |
| Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced that the first patient in the United States (US) was dosed in a global multi-centre phase 3 clinical trial (NCT04740671) of EB12-20145P (HLX04-O), a recombinant anti-VEGF humanised monoclonal antibody injection jointly developed by the Group and Shanghai Henlius Biotech, Inc. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
RAK ICC Strengthens Foundations Regime with 2025 Legislative Enhancements
Aug 16, 2025 15:27 HKT/SGT
|
|
|
WL Delicious Announced 2025 Interim Results
Aug 16, 2025 15:25 HKT/SGT
|
|
|
MMG Announces 2025 Interim Results, Profit, Earnings and Cash up on Strong Copper Growth
Aug 16, 2025 14:55 HKT/SGT
|
|
|
Formerra Becomes North American Distributor for Syensqo PVDF
Aug 16, 2025 14:55 HKT/SGT
|
|
|
Cryofocus Medtech Achieves Record Interim Results with 162% Revenue Surge Driven by Respiratory Intervention Products
Aug 16, 2025 14:54 HKT/SGT
|
|
|
How Do AI Workflow Automations Work?
Aug 16, 2025 00:00 HKT/SGT
|
|
|
Everest Medicines' New Drug Application for Etrasimod Accepted in Taiwan, Marking Another Milestone in Asia Market Access
Aug 15, 2025 23:18 HKT/SGT
|
|
|
Etrasimod Receives Strong Recommendation in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults for Induction and Maintenance Phase of Moderately to Severely Active UC
Aug 15, 2025 20:15 HKT/SGT
|
|
|
OrbusNeich Records Growth in 2025 Interim Results, Revenue and Net Profit Reach US$83.6 Million and US$19.8 Million Respectively
Aug 15, 2025 19:11 HKT/SGT
|
|
|
FWD Group marks 12th anniversary with 12 community grants
Aug 15, 2025 14:14 HKT/SGT
|
|
|
TANAKA Holds Press Conference to Commemorate Its 140th Anniversary
Aug 15, 2025 3:00 JST
|
|
|
The 35th Food Expo opens today
Aug 14, 2025 21:05 HKT/SGT
|
|
|
Re-opening of Food Expo and concurrent fairs
Aug 14, 2025 20:05 HKT/SGT
|
|
|
Yuexiu REIT Maintains Overall Operational Stability, Achieves Revenue of Over RMB966 Million 
Aug 14, 2025 19:15 HKT/SGT
|
|
|
Mitsubishi Corporation to acquire shares in Copper World copper mine project in the US
Aug 14, 2025 12:05 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
